RedShift BioAnalytics, Inc.

RedShift BioAnalytics, Inc. develops advanced analytical instruments for the biopharmaceutical industry, focusing on enhancing drug development processes through innovative technologies. Founded in 2005, RedShift BioAnalytics, Inc. is headquartered in Burlington, US.

The company specializes in analytical instrumentation for protein therapeutic drugs. The CEO is Julien Bradley. In October 2021, RedShift BioAnalytics raised USD 10. 00 mn in Series E funding led by Illumina Ventures, with participation from Technology Venture Partners and Waters Corporation, bringing the total amount raised to USD 10.

00 mn and current company valuation to USD 61. 746 mn. RedShift BioAnalytics specializes in advanced analytical instrumentation designed for the research, development, and manufacturing of protein therapeutic drugs. Their core products include Microfluidic Modulation Spectroscopy (MMS) technology and the HaLCon real-time titer measurement platform, which provides rapid analysis of proteins and biomolecules.

These products are aimed at biopharmaceutical companies, addressing critical challenges in drug discovery and development. RedShift BioAnalytics generates revenue primarily from the sale of its patented analytical instruments and related services to biopharmaceutical companies. The business operates on a B2B model, with direct sales agreements that may include service contracts for ongoing technical support and maintenance of instruments. Their flagship products are positioned as high-value solutions in the industry.

In October 2021, RedShift BioAnalytics raised USD 20 mn in Series E funding to support commercial expansion, continued technology innovation, and product development objectives. The company plans to design and launch new products targeting specific biopharmaceutical markets, while expanding its geographic presence in North America, Europe, and Asia by 2023. This funding will facilitate the execution of these initiatives.